Survodutide: Research Profile, Dosages & Supplier Prices
Survodutide is a glp-1/glucagon agonist compound with a molecular weight of ~4530 g/mol and a research half-life of extended, supporting once-weekly dosing in published trials. Survodutide is a dual GLP-1 and glucagon receptor agonist peptide developed by Boehringer Ingelheim and Zealand Pharma. Published phase 2 data showed substantial weight reduction, and it has drawn particular research attention for MASH (metabolic dysfunction-associated steatohepatitis) trial results showing liver fibrosis improvement.
Research Use Only (RUO). Not for human or veterinary use. Not medical advice.
| Sequence | GLP-1/glucagon dual agonist peptide (structure published in trial literature) |
| Formula | C209H319N45O68 (approximate) |
| Mol. weight | ~4530 g/mol |
| Half-life | Extended, supporting once-weekly dosing in published trials |
| Forms sold | Lyophilized vial (research) |
What is Survodutide?
Research interest covers dual incretin/glucagon pharmacology and hepatic metabolism models.
Survodutide is a newer, complex synthesis. Verify batch-specific third-party mass spec identity when comparing suppliers.
Mechanism of Action (Research Context)
Dual agonist at GLP-1 and glucagon receptors, studied for appetite suppression, energy expenditure, and hepatic fat metabolism.
Research Areas
Survodutide Dosages in Research
Published clinical research titrated once-weekly doses up to 6mg in human trials. Laboratory research use only.
Dosage information is a summary of published laboratory research and is provided for informational purposes only. These compounds are not for human use.
Storage & Handling
Lyophilized: -20C. Reconstituted: 2-8C, use within 30 days.
Survodutide Supplier Price Comparison
| Supplier | Product | Price | Score |
|---|---|---|---|
| Buy Peptides | Survodutide (1 Vial) | $54.99 | ★ 2.3 |